Replies to post #157 on Equity Field Notes from temporal sources

[DanWebzster]

PLX the path forward revolves around completing commercial development for their Fabry treatment without shareholder dilution.

3/18 Management said they had a cash runway through the end of 2019.

The Fabry Ph3 study will be read out mid-2019.

PLX has sought a vote to increase authorized shares by 28% at the next annual meeting during 5/18.

If a partner could be found for at least one of the two next treatments in their pipeline, dilution would almost definitely be avoided. The next treatments in their pipeline are for: 1) Ulcerative Colitis 2) CF

PLX may also be willing to take on debt to avoid dilution.

PLX may again be a tax loss selling candidate.